{"id":"W4410140470","doi":"10.1182/bloodadvances.2025016042","title":"Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; Astellas Pharma; National Institute for Health and Care Research; National Cancer Institute; Incyte; Sanofi; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Bosutinib; Tolerability; Discontinuation; Medicine; Adverse effect; Internal medicine; Oncology; Myeloid leukemia; Imatinib; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002639072,0.0004960629,0.001428256,0.0002254881,0.0003442724,0.001252847,0.0003438783,0.0006700331,0.002688595],"category_scores_gemma":[0.001984083,0.0002103322,0.001763338,0.0004152279,0.000239043,0.0008139078,0.0003797497,0.002477763,0.0004900427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009830254,"about_ca_system_score_gemma":0.0007563792,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007359381,"about_ca_topic_score_gemma":0.00134383,"domain_scores_codex":[0.9992062,0.0002572771,0.00007957329,0.0001778358,0.00009422386,0.0001848425],"domain_scores_gemma":[0.9983985,0.0003325164,0.0004648493,0.0001505928,0.0001590031,0.0004944714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6762549,0.00908512,0.07128327,0.000723111,0.004353457,0.0004923198,0.0003047969,0.001927497,0.01791082,0.0004252023,0.007120475,0.210119],"study_design_scores_gemma":[0.134616,0.395731,0.424819,0.0003640149,0.006361743,0.001136908,0.0002837541,0.006143268,0.01192526,0.0007439287,0.01775438,0.0001207939],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901454,0.005641411,0.0003616934,0.0004804445,0.0001299303,0.0001370097,0.001551925,0.00004368452,0.001508443],"genre_scores_gemma":[0.9961542,0.0005883498,0.0001607623,0.0004230168,0.00008502082,0.00006872522,0.001577955,0.000006449131,0.0009353482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002688595,"threshold_uncertainty_score":0.0139569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009538012546709346,"score_gpt":0.2806488671159375,"score_spread":0.2711108545692281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}